Estrogens in vascular biology and disease:: where do we stand today?

被引：59
|
作者：
Arnal, Jean-Francois
Scarabin, Pierre-Yves
Tremollieres, Florence
Laurell, Henrik
Gourdy, Pierre
机构：
[1] CHU Toulouse Rangueil, Dept Vasc Biol & Atherothrombosis, INSERM, U858,12MR, F-31432 Toulouse 4, France
[2] Hop Paul Brousse, Cardiovasc Epidemiol Team, Villejuif, France
来源：
CURRENT OPINION IN LIPIDOLOGY | 2007年 / 18卷 / 05期
关键词：
atheroma; atherosclerosis; cardiovascular risk; oestrogens; thrombosis;
D O I：
10.1097/MOL.0b013e3282ef3bca
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
A better understanding of the balance between the deleterious and beneficial effects of estrogens is required and should help to improve hormonal therapy safety and to optimize the prevention of cardiovascular disease after menopause.
引用
收藏
页码：554 / 560
页数：7
相关论文
共 50 条
  • [21] Resting Heart Rate and Outcomes in Patients with Cardiovascular Disease: Where Do We Currently Stand?
    Menown, Ian B. A.
    Davies, Simon
    Gupta, Sandeep
    Kalra, Paul R.
    Lang, Chim C.
    Morley, Chris
    Padmanabhan, Sandosh
    CARDIOVASCULAR THERAPEUTICS, 2013, 31 (04) : 215 - 223
  • [22] Diagnosis and management of obstetrical antiphospholipid syndrome: where do we stand?
    Marchetti, Tess
    Cohen, Marie
    Gris, Jean-Christophe
    de Moerloose, Philippe
    POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ-POLISH ARCHIVES OF INTERNAL MEDICINE, 2013, 123 (12): : 1 - 7
  • [23] Primary Thromboprophylaxis in Ambulatory Cancer Patients: Where Do We Stand?
    Mulder, Frits I.
    Bosch, Floris T. M.
    van Es, Nick
    CANCERS, 2020, 12 (02)
  • [24] Vitamin D and cardiovascular diseases: where do we stand in 2012?
    Pilz, Stefan
    Maerz, Winfried
    LABORATORIUMSMEDIZIN-JOURNAL OF LABORATORY MEDICINE, 2012, 36 (05): : 281 - 289
  • [25] Co-treatment of lower urinary tract symptoms and cardiovascular disease - where do we stand?
    Semczuk-Kaczmarek, Karolina
    Platek, Anna E.
    Szymanski, Filip M.
    CENTRAL EUROPEAN JOURNAL OF UROLOGY, 2020, 73 (01) : 42 - 45
  • [26] Lipoprotein(a) Where Do We Stand? From the Physiopathology to Innovative Terapy
    Iannuzzo, Gabriella
    Tripaldella, Maria
    Mallardo, Vania
    Morgillo, Mena
    Vitelli, Nicoletta
    Iannuzzi, Arcangelo
    Aliberti, Emilio
    Giallauria, Francesco
    Tramontano, Anna
    Carluccio, Raffaele
    Calcaterra, Ilenia
    Di Minno, Matteo Nicola Dario
    Gentile, Marco
    BIOMEDICINES, 2021, 9 (07)
  • [27] Single-nucleotide polymorphisms and their role in coronary artery disease: Where do we stand now?
    Papageorgiou, Nikolaos
    Tousoulis, Dimitris
    HELLENIC JOURNAL OF CARDIOLOGY, 2018, 59 (01) : 14 - 15
  • [28] Letter by Virmani et al Regarding Article, "Drug-Eluting Stents in Animals and Patients: Where Do We Stand Today?"
    Virmani, Renu
    Wilson, Gregory J.
    Finn, Aloke Virmani
    CIRCULATION, 2010, 121 (11) : E246 - E246
  • [29] The rote of ezetimibe in the prevention of cardiovascular disease: Where do we stand after ARBITER 6-HALTS
    Howard, Wm. J.
    NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2010, 20 (05) : 295 - 300
  • [30] Hyperhomocysteinemia in health and disease: where we are now, and where do we go from here?
    Lippi, Giuseppe
    Plebani, Mario
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2012, 50 (12) : 2075 - 2080
12345